Micronised progesterone is a body-identical hormone that shares the same molecular structure as the progesterone your body naturally makes. Unlike synthetic progestogens, it appears to carry a more favourable safety profile for breast health, sleep, and cardiovascular wellbeing, making it the preferred progestogen choice in current menopause care guidelines.
If you have a uterus and are exploring menopausal hormone therapy (MHT), you will encounter two types of progesterone: micronised progesterone and synthetic progestogens. They perform the same core function — protecting the uterine lining from oestrogen's stimulating effects — but the similarities largely end there.
This article explains what micronised progesterone is, how it differs from synthetic alternatives, and what current evidence says about its benefits for sleep disorders, breast health, and cardiovascular wellbeing during perimenopause and menopause.
Progesterone is a steroid hormone produced by the ovaries, primarily after ovulation. During the reproductive years, it rises and falls in a predictable monthly rhythm. As you approach perimenopause, these levels become increasingly erratic before declining significantly in postmenopause.
Micronised progesterone is progesterone finely ground into tiny particles and suspended in an oil-based capsule. This process dramatically improves absorption into the bloodstream — before micronisation, oral progesterone was poorly absorbed and largely inactive.
Crucially, micronised progesterone is "body-identical": its molecular structure is chemically identical to the progesterone your body produces. It is not a copy or approximation; it is the same molecule. Synthetic progestogens, by contrast, are chemically modified versions designed to act like progesterone but with a different structure.
The Australasian Menopause Society classifies pharmaceutical-grade micronised progesterone — available in Australia as Prometrium and in New Zealand as Utrogestan — as an approved regulated body-identical hormone [5].
Note: Micronised progesterone is a commercially available body-identical hormone listed in the ARTG (Prometrium 100 mg: ARTG 232818; Prometrium 200 mg: ARTG 232823). This is distinct from compounded bioidentical preparations, which are not subject to the same quality and consistency standards and are generally a secondary option when commercial products cannot meet a patient's specific needs.
The core difference lies in molecular structure — and that structure determines how each hormone interacts with your body.
Micronised progesterone binds almost exclusively to progesterone receptors. Because it is identical to endogenous progesterone, its effects align closely with what your body expects and recognises. It does not carry androgenic (testosterone-like) or glucocorticoid (cortisol-like) activity to any meaningful degree.
Synthetic progestogens (also called progestins) are chemically modified versions of progesterone or testosterone. They were developed partly for practical reasons — synthetic hormones are often more potent and easier to manufacture — but their altered structures mean they can interact with a wider range of hormone receptors. This can produce effects that are not characteristic of natural progesterone, including androgenic activity in some cases, which may affect lipid profiles, mood, and the risk-benefit balance of MHT overall.
A 2021 review published in Women & Health noted that progestogens differ by their biological activities, and it is unlikely that all progestogens display a class effect — meaning what is true for one is not necessarily true for another [1]. This is clinically significant because many of the concerns historically raised about MHT (particularly following older studies) were based on trials using synthetic progestogens rather than micronised progesterone.
Current reviews increasingly favour micronised progesterone as the progestogen of choice in MHT regimens when a woman has an intact uterus [1][2]. Transdermal oestrogen combined with micronised progesterone is generally preferred, partly because this combination appears to offer the most favourable safety profile overall [2].
One of the most important reasons micronised progesterone is preferred relates to breast cancer risk. Much of the concern about MHT breast risk originates from trials that used synthetic progestogens — and subsequent analyses suggested the synthetic progestogen component was a key driver.
A 2025 narrative review in the Journal of Clinical Medicine concluded that oestradiol combined with micronised progesterone is associated with a lower risk of breast cancer compared with MHT regimens containing synthetic progestogens [2]. Studies indicate that for the first five years of use, the combination does not appear to increase breast cancer risk, with some analyses suggesting the advantage persists beyond five years.
A landmark randomised controlled trial — the PROBES study — is currently underway in Sweden, directly comparing micronised progesterone with a synthetic progestogen (norethisterone acetate) for breast density and endometrial safety. Published in BMJ Open in 2024, the protocol notes that observational evidence supports micronised progesterone's favourable breast safety profile, but randomised trial data are still needed [3].
For women with a personal or family history of breast concerns, the progestogen type is a clinically relevant consideration worth discussing with a menopause-focused doctor.
Sleep disorders, mood swings, and anxiety are among the most commonly reported and disruptive symptoms of perimenopause and menopause. Micronised progesterone has a unique advantage here that synthetic progestogens do not share.
When progesterone is metabolised in the body, it produces neuroactive compounds, including allopregnanolone, which acts as a positive modulator of GABA-A receptors — the same receptors targeted by benzodiazepines and other sedative medications. This means micronised progesterone has a naturally calming, sleep-promoting action.
A 2021 systematic review and meta-analysis in The Journal of Clinical Endocrinology & Metabolism analysed nine randomised controlled trials (388 participants) and found that micronised progesterone significantly improved sleep onset latency compared with placebo, with most trials also showing improvements in self-reported sleep quality [4]. Because of this sedative effect, bedtime administration is standard practice.
Synthetic progestogens do not undergo the same metabolic conversion and therefore lack these neuroactive benefits. For women struggling with night sweats or sleep disruption, this distinction can be meaningful in treatment planning.
Some women report that synthetic progestogens negatively affect mood, particularly during cyclical use. Micronised progesterone, through its GABA-modulating metabolites, tends to be better tolerated — though individual responses vary.
If you are experiencing fatigue, irritability, or sleep difficulties, discussing your menopause treatment options with a specialist is worthwhile, as the type of progestogen can make a real difference.
Cardiovascular health is a key consideration in MHT, and the progestogen component can influence whether oestrogen's cardiovascular effects are beneficial or neutral.
A 2025 narrative review found that micronised progesterone appears neutral or even beneficial for coagulation and cardiovascular markers, whereas some synthetic progestins have been associated with adverse lipid changes and increased venous thromboembolism (VTE) risk [2]. This is relevant to route of oestrogen delivery: transdermal oestrogen combined with micronised progesterone is generally considered the combination with the most favourable VTE risk profile, making it a commonly preferred approach for women with cardiovascular risk factors.
Tip: Transdermal oestrogen bypasses first-pass liver metabolism, which appears to reduce the risk of blood clots. Paired with micronised progesterone, this combination is widely considered to have a favourable safety profile for most women. Your doctor will assess your individual circumstances to determine the right approach.
For women with an intact uterus taking oestrogen therapy, a progestogen is essential. Oestrogen alone stimulates the uterine lining (endometrium) over time, increasing the risk of endometrial hyperplasia and cancer. A progestogen counteracts this effect.
Micronised progesterone provides effective endometrial protection when dosed appropriately [2]. Recommended doses are 200 mg for 12 days per month on a cyclical regimen, or 100 mg daily on a continuous regimen. Some observational data suggest it may be marginally less potent at endometrial suppression than certain synthetic alternatives at higher oestrogen exposures — a question the PROBES trial [3] is directly investigating. For most women at standard doses, protection is considered effective, and individualised monitoring by a clinician is important.
Essentially, yes. Micronised progesterone is body-identical: its molecular structure is identical to the progesterone your body produces. The term "bioidentical" is used loosely in some contexts and can refer to both commercially available products listed in the ARTG (like Prometrium, ARTG 232818/232823) and unregulated compounded preparations. For consistent quality and safety, ARTG-listed micronised progesterone is recommended over custom-compounded alternatives.
Women who have an intact uterus and are using oestrogen therapy need to take a progestogen to protect the uterine lining. Women who have had a hysterectomy generally do not need a progestogen component. Your doctor will assess your specific situation.
Unlike some synthetic progestogens, micronised progesterone does not appear to be associated with significant weight gain. However, menopause itself can influence body composition due to hormonal changes and reduced muscle mass. If weight gain is a concern, a comprehensive approach including nutrition and lifestyle support alongside MHT is worth exploring.
Research is mixed. A 2023 Canadian Phase III trial of 300 mg oral micronised progesterone in perimenopausal women did not find a statistically significant objective reduction in hot flushes and night sweats versus placebo, though women reported subjective improvements in night sweats and sleep quality [6]. Some clinicians use it to support sleep and mood during perimenopause when progesterone levels begin to fluctuate erratically.
It is most commonly taken orally at bedtime, due to its mild sedative effect. It can also be used vaginally in certain circumstances, without the same sedative action. The appropriate dose, route, and regimen are determined with your doctor based on your symptoms and health history.
Micronised progesterone represents an important evolution in how we approach hormone therapy for menopause. As a body-identical hormone, it interacts with the body in ways that are closer to natural physiology than synthetic alternatives, and current evidence suggests meaningful advantages for breast health, sleep, mood, and cardiovascular wellbeing.
For women managing the signs and symptoms of menopause, knowing that the type of progestogen matters — not just whether you take one — is an empowering insight. It is one of many reasons that personalised care from a menopause-focused clinician, rather than a one-size-fits-all approach, makes such a difference.
At the Australian Menopause Centre, our menopause-focused doctors take the time to understand your full health picture before recommending any treatment program. With over 20 years of experience supporting Australian women through perimenopause and beyond, we provide accessible, evidence-based care via telehealth — no referral needed, no lock-in contracts, and bulk-billed consultations available Australia-wide.
Want to know if micronised progesterone is right for you? Our menopause-focused doctors can help you weigh the benefits and risks based on your personal health history. Book a bulk-billed consultation — no referral needed.
This information is for educational purposes only and is not medical advice. Consult your healthcare provider for personalised recommendations. Hormone therapy is not suitable for everyone. Your doctor will assess whether it's appropriate for you based on your individual health history, symptoms, and risk factors. Individual results may vary.